Multiple Sclerosis Clinical Trials

Diclofenac Sodium Topical Gel (Voltaren)

Phase IV

To Reduce injection site discomfort in patients with Multiple Sclerosis taking Copaxone: A randomized controlled double-blind crossover trial

Description
To assess the effect of diclofenac sodium topical gel (DSTG) on local injection site reaction and pain following Copaxone (Glatiramer acetate) administration.

Currently Enrolling

Who Can Participate?
Stable patients with clinically definite MS, aged 18 and over taking Copaxone.

Investigator: Theodore Brown, MD

For More Information: - Carey Gonzales 425.899.5374 - clgonzales@evergreenhealthcare.org

205MS301 DECIDE

NCT01064401
Phase III

Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β 1a) in Patients with Relapsing-Remitting Multiple Sclerosis

Description
The main purpose of the study is to see if DAC HYP is more effective in helping people with MS than Avonex®, an approved treatment for MS. Additionally, this study will (a) see if DAC HYP causes participants' bodies to develop antibody biomarkers Testing biomarkers can help evaluate how well and safely the study drugs may work in MS. A subject will participate in this study for at least 96 weeks but no more than 144 weeks.

Not Enrolling

Who Can Participate?
Around 1,500 participants who are between the ages of 18 and 55 are planned to be enrolled in this study at approximately 280 study sites. Confirmed diagnosis of Relapsing Remitting MS.

Investigator: Virginia Simnad, MD

For More Information: Shalom Kilcup 425.899.5369 sekilcup@evergreenheathcare.org

Dalfampridine ER (Ampyra)

Phase IV

A randomized controlled double-blind cross-over trial of Dalfampridine ER for effect on ambulatory activity in people with Multiple Sclerosis.

Description
Parallel-group, double-blind randomized controlled crossover trial. There are two treatment periods of 4 weeks and a tow-week off-treatment washout period. Treatment periods a DER followed by placebo (Group A) and placebo followed by DER (Group B), respectively. All dosages will be administered bid (twice a day).

Currently Enrolling

Who Can Participate?
Patients with confirmed diagnosis of MS and MS-related limited capacity for physical activity defined by screening 6 meter timed walk in the range of 50-505 meters. They must have no history of seizures or renal disease

Investigator:  Theodore Brown, MD

For More Information: Shalom Kilcup 425.899.5369 sekilcup@evergreenheathcare.org

Duloxetine

NCT00457730
Phase II/III

A randomized placebo controlled trial of Duloxetine for central pain in multiple sclerosis

Description
To determine whether duloxetine is effective in relieving central pain in MS, as measured by a reduction in the weekly 24-hour worst pain score.

Currently Enrolling

Who Can Participate?
MS patients who are older than 18 and have central and persistent pain symptoms

Investigator: Theodore Brown, MD

For More Information: Carey Gonzales 425.899.5374 clgonzales@evergreenhealthcare.org

Gala

NCT01067521
Phase III

A multinational, multicenter, randomized, parallel-group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of Glatiramer Acetate (GA) injection 40 mg/ml administered three times a week compared to placebo in a double-blind design

Description
To assess the efficacy, safety and tolerability of Glatiramer Acetate (GA) injection 40 mg/ml administered three times a week compared to placebo in a double-blind study design.

Not enrolling

Who Can Participate?
MS patients between 18- 55 who had one relapse in the past year or 2 relapses in two years; must be ambulatory without an aid or rest for at least 330 feet

Investigator: Virginia Simnad, MD

For More Information: Shalom Kilcup - 425.899.5369 - sekilcup@evergreenhealthcare.org

Stratify - 2

NCT01070836
Phase IIII

JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri: Stratify- 2

Description
Blood samples will be collected from at least 8,000 patients in the United States with Multiple Sclerosis (MS). Participation in Stratify- 2 is voluntary and is expected to last 2 years. There is no drug treatment provided in this study.

Not Enrolling

Who Can Participate?
U.S patients with Relapsing MS receiving commercial Tysabri and patients being considered for such treatment.

Investigator: Virginia Simnad, MD

For More Information: Carey Gonzales 425.899.5374 clgonzales@evergreenhealthcare.org

HHD- Hand Held Dynamometer

A cross-sectional study
Validation of a hand-held dynamometer for assessment of lower limb muscle strength in multiple sclerosis: Protocol for strength testing and reliability characteristics.

Description 
The purpose of the study is to demonstrate the method of testing the strength of five key lower limb muscle groups using a hand held strength device compared to an examiners manual rating of strength. There are 2 visits required during this study, taking place over a 3 week period.

Soon to begin Enrollment

Who can participate?
Clinically stable patients with definite MS. No change in disease modifying therapy for 30 days prior to screening. Age 18 and over.

Investigator:  Theodore Brown, MD

For More Information: Carey Gonzales 425-899-5374  clgonzales@evergreenhealthcare